Fmr Llc Cashes In on Metsera, Inc. Stock Sale!

New insider activity at Metsera, Inc. ( (MTSR) ) has taken place on November 5, 2025.

Fmr Llc recently sold 193 shares of Metsera, Inc. stock, generating a total of $11,815 from the transaction.

Recent Updates on MTSR stock

In the last 24 hours, Metsera, Inc. (MTSR) experienced a significant stock price increase of 17.7%, reaching $71.50. This surge follows the company’s announcement that it received a revised acquisition proposal from Novo Nordisk, which was deemed a ‘Superior Company Proposal’ compared to the existing merger agreement with Pfizer. Novo Nordisk’s proposal values Metsera at approximately $10 billion, offering $62.20 per share in cash and contingent value rights up to $24.00 per share, surpassing Pfizer’s offer of up to $70.00 per share. This development has triggered a two-day negotiation period with Pfizer to potentially adjust their merger terms. Despite this, Metsera’s Board continues to recommend the Pfizer merger to shareholders. The trading of Metsera’s stock was temporarily halted pending this news but has since resumed.

Spark’s Take on MTSR Stock

According to Spark, TipRanks’ AI Analyst, MTSR is a Underperform.

Metsera, Inc. faces significant challenges, primarily due to its lack of revenue and ongoing financial losses, which are critical concerns for long-term viability. The technical analysis indicates bearish momentum, reinforcing negative sentiment. Valuation metrics are limited, as the company does not have earnings or dividends. Despite a strong cash position, the high cash burn rate poses a risk. Overall, the lack of revenue and negative technical indicators weigh heavily on the stock’s potential.

To see Spark’s full report on MTSR stock, click here.

More about Metsera, Inc.

YTD Price Performance: 176.15%

Average Trading Volume: 2,402,918

Technical Sentiment Signal: Strong Buy

Current Market Cap: $7.71B